CLCN3 and neoplasm: CLC3 knockdown, combined with cisplatin treatment, led to a significant reduction in tumor volume compared to the control and cisplatin-alone groups, indicating that CLC3 downregulation enhances sensitivity to cisplatin (Fig. 6A).